Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis

Conclusions With an incidence of 4 out of 1000 patients osteonecrosis is a rare side effect of anti-angiogenic agent. With the increasing utilisation and duration of exposure of anti-VEGF therapy some rare side effect due to chronic ischemia may appear. The clinician should be aware about uncommon symptoms.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research